Design of the First-in-Human study of IONIS-MAPTRx, a Tau-lowering antisense oligonucleotide, in patients with alzheimer disease (S2.006)

BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease

Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H. Y., & Al‐Tel, T. H. (2019) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 308 · see citing works

A walk through tau therapeutic strategies

Jadhav, S., Ávila, J., Schöll, M., Kovács, G. G., Kövari, E., Škrabana, R., Evans, L., Kontseková, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 286 · see citing works

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models

Silva, M. C., Ferguson, F. M., Cai, Q., Donovan, K. A., Nandi, G., Patnaik, D., Zhang, T., Huang, H.-T., Lucente, D. E., Dickerson, B. C., et al. (2019) · eLife · doi:10.7554/elife.45457 · Cited by 283 · see citing works

Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons

Silva, M. C., Nandi, G. A., Tentarelli, S., Gurrell, I. K., Jamier, T., Lucente, D., Dickerson, B. C., Brown, D. G., Brandon, N. J., & Haggarty, S. J. (2020) · Nature Communications · doi:10.1038/s41467-020-16984-1 · Cited by 157 · see citing works

The human motor cortex microcircuit: insights for neurodegenerative disease

McColgan, P., Joubert, J., Tabrizi, S. J., & Rees, G. E. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-0315-1 · Cited by 86 · see citing works

Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies

Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 87 · see citing works

A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12453 · Cited by 72 · see citing works

Therapy for Alzheimer’s disease: Missing targets and functional markers?

Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 72 · see citing works

Alzheimer’s disease and related tauopathies: disorders of disrupted neuronal identity

Frost, B. E. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.006 · Cited by 56 · see citing works

Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases

Helm, J., Schöls, L. J., & Hauser, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081708 · Cited by 47 · see citing works

Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies

Annadurai, N., Sanctis, J. B. D., Hajdúch, M., & Das, V. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113756 · Cited by 41 · see citing works

Targeting epigenetics: A novel promise for Alzheimer’s disease treatment

Jeremic, D., Jiménez‐Díaz, L., & Navarro‐López, J. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102003 · Cited by 36 · see citing works

Tau; One Protein, So Many Diseases

Tabeshmehr, P., & Eftekharpour, E. (2023) · Biology · doi:10.3390/biology12020244 · Cited by 33 · see citing works

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies

Easton, A. E., Jensen, M. L., Wang, C., Hagedorn, P., Li, Y.-W., Weed, M. R., Meredith, J. E., Guss, V. L., Jones, K. M., Gill, M. B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.027 · Cited by 27 · see citing works

Diligent Design Enables Antibody-ASO Conjugates with Optimal Pharmacokinetic Properties

Sela, T., Mansø, M., Siegel, M., Marban-Doran, C., Ducret, A., Niewöhner, J., Ravn, J., Martin, R. E., Sommer, A., Lohmann, S., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00393 · Cited by 21 · see citing works

The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies

Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2200245 · Cited by 19 · see citing works

FTLD Treatment: Current Practice and Future Possibilities

Ljubenkov, P. A., & Boxer, A. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_18 · Cited by 13 · see citing works

Unraveling the tau puzzle: a review of mechanistic targets and therapeutic interventions to prevent tau pathology in Alzheimer’s disease

Kammula, S. V., Tripathi, S., Wang, N., Dawson, V. L., Dawson, T. M., & Mao, X. (2023) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2023.20 · Cited by 9 · see citing works

The tauopathies: Neuroimaging characteristics and emerging experimental therapies

Riley, K. J., Graner, B. D., & Veronesi, M. C. (2022) · Journal of Neuroimaging · doi:10.1111/jon.13001 · Cited by 7 · see citing works

Alzheimer’s Disease Pharmacology

Plascencia‐Villa, G., & Perry, G. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00018-9 · Cited by 6 · see citing works

Emerging drugs for progressive supranuclear palsy

Giagkou, N., & Stamelou, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1609450 · Cited by 6 · see citing works

Alternative splicing in Alzheimer's disease: Mechanisms, therapeutic implications, and 3D modeling approaches

Pasteris, M., Çakır, S., Bellizzi, A., & Sariyer, I. K. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251359633 · Cited by 4 · see citing works

Clinical Trial Development in Frontotemporal Lobar Degeneration

Ljubenkov, P. A., & Boxer, A. L. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.019 · Cited by 3 · see citing works

Toward nanomedicine-enabled RNA therapeutics for Alzheimer’s disease

Kara, G., & Villapol, S. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00026-z · Cited by 3 · see citing works

A state-of-the-art review on miRNA in prevention and treatment of Alzheimer’s disease

Guo, X. (2023) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2023-0324 · Cited by 2 · see citing works

Nucleic Acid-Based Therapeutics Relevant to Neuroimmune Conditions

Greenfield, A. L., & Hauser, S. L. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00740-5 · Cited by 2 · see citing works

Evaluating the efficacy of commercially available antisense oligonucleotides to reduce mouse and human tau in vivoPreprint

Vemula, P., Schoch, K. M., & Miller, T. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.29.522258

Study of the Neuron-Astrocyte Relationship in a Rodent Model of Tauopathy

de Gérando, A. M. (2019) · theses.fr (ABES) · doi:10.70675/04658671zaca3z4fefza24dz2f5a011bebfe

Caractérisation et modulation du microbiote intestinal dans le contexte de la maladie d’Alzheimer : vers une nouvelle piste thérapeutique

Ismeurt, C. (2021) · theses.fr (ABES) · doi:10.70675/159d4638zb5f8z4580zb26fzd0419dba4d37

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Genentech taps Affimed’s antibodies

Cross, R. (2018) · C&EN Global Enterprise · doi:10.1021/cen-09635-buscon15

KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK

Sari, D. (2023) · Jurnal Komplikasi Anestesi · doi:10.22146/jka.v5i1.7322

Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria

Dib, A., Puig, L. B., Salvadori, D., et al. (1988) · Arquivos Brasileiros de Cardiologia

Interleucinas na encefalopatia hipóxico-isquêmica

Ceccon, M. E. J. R. (2003) · Jornal de Pediatria · doi:10.1590/s0021-75572003000400002 · Cited by 14 · see citing works